keyword
MENU ▼
Read by QxMD icon Read
search

exviera

keyword
https://www.readbyqxmd.com/read/27570996/-suicidal-ideation-in-patients-treated-with-ombitasvir-paritaprevir-ritonavir-viekirax%C3%A2-dasabuvir-exviera%C3%A2-and-ribavirina-rebetol%C3%A2
#1
Jose Carlos De Miguel Bouzas, Eva Castro Tubío, Leticia Herrero Poch, Carlos González Portela
No abstract text is available yet for this article.
September 2016: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/27280194/dasabuvir-exviera-only-assessed-as-part-of-a-difficult-to-manage-combination-in-hepatitis-c
#2
(no author information available yet)
In late 2015, the first-choice treatment for patients with chronic hepatitis C due to a genotype 1 virus (HCV-1) was the combination of ledipasvir (an NS5A protein inhibitor) + sofosbuvir (a nucleotide inhibitor of NS5B RNA polymerase), despite major uncertainties regarding its adverse effects. This combination is almost always virologically effective. Dasabuvir is a non-nucleoside inhibitor of the viral RNA polymerase NS5B. It is authorised in the EU for the treatment of patients with chronic hepatitis C due to HCV-1, usually combined with the fixed-dose combination (Viekirax) of ombitasvir (an HCV NS5A protein inhibitor) + paritaprevir (an HCV protease inhibitor) + ritonavir (to enhance paritaprevir bioavailability)...
May 2016: Prescrire International
https://www.readbyqxmd.com/read/26059288/ombitasvir-paritaprevir-ritonavir-plus-dasabuvir-a-review-in-chronic-hcv-genotype-1-infection
#3
REVIEW
Emma D Deeks
A fixed-dose tablet comprising ombitasvir (an NS5A replication complex inhibitor), paritaprevir (an NS3/4A protease inhibitor) and ritonavir (a cytochrome P450 inhibitor) taken in combination with dasabuvir (an NS5B polymerase inhibitor) is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in several countries, including the USA (copackaged as Viekira Pak(™)) and those of the EU (Viekirax(®) and Exviera(®)). In phase II and III trials, this interferon-free regimen, taken ± ribavirin, provided high rates of sustained virological response 12 weeks post-treatment in adults with chronic HCV genotype 1a or 1b infection, including those with compensated cirrhosis, liver transplants or HIV-1 co-infection...
June 2015: Drugs
https://www.readbyqxmd.com/read/25937625/interferon-free-therapy-for-hepatitis-c-the-hurdles-amid-a-golden-era
#4
REVIEW
Massimo Colombo
The long awaited all-oral therapy for hepatitis C virus infection has officially been inaugurated by the registration of the hepatitis C nucleotide inhibitor sofosbuvir in a combination regimen with ribavirin. More recently, the oral array to treat hepatitis C has been enriched by the arrival of the NS5A inhibitors ledipasvir (also in a single formulation with sofosbuvir, Harvoni(®)) and daclatasvir; the protease inhibitor simeprevir, and the Viekirax(®)+Exviera™ regimen based on the ritonavir boosted protease inhibitor paritaprevir; the NS5A inhibitor ombitasvir, and the non-nucleoside inhibitor dasabuvir...
September 2015: Digestive and Liver Disease
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"